Constitutional Challenge Threatens DEA Rescheduling Timeline

The Constitutional Question

The challenge invokes the nondelegation doctrine, which prohibits Congress from transferring its legislative powers to administrative agencies without intelligible principles to guide their exercise. Legal scholars cited in recent federal court filings argue the CSA's five-factor test for scheduling — abuse potential, scientific evidence, public health risk, psychic or physiological dependence, and whether the substance is an immediate precursor of a controlled substance — lacks the specificity required under the Constitution's Article I vesting clause.

The argument isn't new. Similar nondelegation challenges to administrative rulemaking have gained traction in federal appellate courts since 2019, when the Fifth Circuit struck down portions of the Securities Exchange Act in Jarkesy v. SEC. That decision, now on appeal to the Supreme Court, revived a doctrine largely dormant since the 1930s.

What makes this challenge different is its timing. Filed in the D.C. Circuit on June 9, 2026, it targets the DEA's ongoing rescheduling proceeding for cannabis — a process the agency kicked off in May 2024 after a Health and Human Services Department recommendation to move cannabis from Schedule I to Schedule III.

Impact on the DEA Rescheduling Timeline

If the challenge succeeds, the DEA would lack constitutional authority to reschedule cannabis without new legislation from Congress spelling out precise criteria for drug classification. That outcome would freeze the current Schedule I designation indefinitely, barring congressional action.

The DEA hasn't yet issued a final rule on rescheduling. The agency's Notice of Proposed Rulemaking, published in May 2024, drew more than 43,000 public comments during a 60-day window. Administrative law experts told CannIntel the agency is likely conducting interagency review before finalizing the rule — a process that typically takes 12 to 18 months from NPRM publication.

The constitutional question isn't whether cannabis should be rescheduled, but whether any executive agency has the power to make that call without explicit direction from Congress.

The D.C. Circuit filing doesn't seek to halt the rescheduling process immediately. Instead, it asks the court to declare the CSA's delegation unconstitutional and enjoin the DEA from finalizing any rescheduling decision until Congress enacts a constitutionally compliant framework. For context on the broader rescheduling effort, see the CannIntel topic hub on DEA rescheduling.

The Petitioners and Their Strategy

The challenge was filed by a coalition including the Institute for Justice, a libertarian public-interest firm, and two individual plaintiffs with prior federal cannabis convictions. Court records show the plaintiffs argue their past prosecutions under the CSA were constitutionally defective because the statute improperly delegated scheduling authority to the executive branch.

The Institute for Justice has litigated nondelegation claims in other contexts, including occupational licensing and civil asset forfeiture. Its involvement signals a coordinated strategy to use cannabis rescheduling as a vehicle for broader administrative-law reform.

One wrinkle: the plaintiffs don't oppose cannabis legalization. Their brief explicitly states they support rescheduling or descheduling cannabis, but insist the policy change must come from Congress, not the DEA. That posture may complicate the political optics, since cannabis-reform advocates typically view DEA rescheduling as the fastest path to federal change.

What Happens Next

The D.C. Circuit hasn't yet set a briefing schedule, and the DEA has 60 days to file its response. Legal observers expect the agency to argue the CSA's five-factor test provides sufficient guidance under existing Supreme Court precedent, which has upheld broad delegations in cases like Whitman v. American Trucking Associations (2001) and Gundy v. United States (2019).

If the circuit court sides with the plaintiffs, the DEA would almost certainly appeal to the Supreme Court. Given the current Court's skepticism of administrative power — evidenced by decisions in West Virginia v. EPA (2022) and Loper Bright Enterprises v. Raimondo (2024) — the outcome is far from certain.

Three variables will determine the timeline. Will the D.C. Circuit grant expedited review? Will the Supreme Court take the case if appealed? Will Congress preempt the litigation by passing new scheduling legislation? None of those outcomes is likely before mid-2027.